Accueil   Diary - News   All news Calixar invests €1 Million in pipeline of highly druggable membrane protein targets and native antigens

Calixar invests €1 Million in pipeline of highly druggable membrane protein targets and native antigens

 

 

Calixar’s pipeline will prioritize membrane therapeutic proteins
validated by pharmaceutical companies

 

 

The high-relevance and ‘ready-for-drug discovery’ membrane targets will be accessible for exclusive licensing

 

Lyon, France, April 12, 2021 – Calixar, a biotechnology company with ten years expertise in the isolation of fully native membrane proteins, today announces its €1M ($1.2M) investment in a new pipeline of complex therapeutic targets and native antigens of high relevance for pharmaceutical companies. This strategic investment, supported by Bpifrance investment bank, will enable the company to be the exclusive provider and licensor for pharmaceutical companies, with the best native and functional membrane therapeutic targets (GPCRs, ion channels, transporters, receptors and viral targets). It will also help them to discover the best drugs (small molecules and conformational antibodies) and develop the best vaccines.

 

 

Read the press release